BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Operating income 2016–2025
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) annual operating income history from SEC filings — each fiscal year as reported.
-$10.0MFY2025 · since FY2016: -$5.1M → -$10.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$10.0M | +14.9% |
| FY2024 | -$11.7M | +45.5% |
| FY2023 | -$21.4M | +13.6% |
| FY2022 | -$24.8M | -1.2% |
| FY2021 | -$24.5M | +22.6% |
| FY2020 | -$31.7M | -37.8% |
| FY2019 | -$23.0M | -63.6% |
| FY2018 | -$14.1M | -181.3% |
| FY2017 | -$5.0M | +1.7% |
| FY2016 | -$5.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BCLI financial trends
BCLI RevenueBCLI Net incomeBCLI Net marginBCLI Gross profitBCLI Gross marginBCLI Operating marginBCLI Operating cash flowBCLI Free cash flowBCLI Capital expendituresBCLI Return on equityBCLI Stock buybacksBCLI Dividends paidBCLI Total assetsBCLI Total liabilitiesBCLI Shareholders’ equityBCLI overview →